Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999

M. Tsuchida, A. Ohara, A. Manabe, M. Kumagai, Hiroyuki Shimada, A. Kikuchi, T. Mori, M. Saito, M. Akiyama, T. Fukushima, K. Koike, M. Shiobara, C. Ogawa, T. Kanazawa, Y. Noguchi, S. Oota, Y. Okimoto, H. Yabe, M. Kajiwara, D. TomizawaK. Ko, K. Sugita, T. Kaneko, M. Maeda, T. Inukai, H. Goto, H. Takahashi, K. Isoyama, Y. Hayashi, R. Hosoya, R. Hanada

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999. The value of event-free survival (EFS)s.±e. was 67.2±2.2% at 10 years in L84-11, which was not improved in the following two studies, and eventually improved to 75.0±1.8% at 10 years in L95-14 study. The lower EFS of the L89-12 reflected a high rate of induction failure because of infection and delayed remission in very high-risk patients. The L92-13 study was characterized by short maintenance therapy; it resulted in poor EFS, particularly in the standard-risk (SR) group and boys. Females did significantly better than males in EFS in the early three studies. The gender difference was not significant in overall survival, partly because >60% of the males survived after the testicular relapse. Randomized studies in the former three protocols revealed that intermediate-or high-dose methotrexate therapy significantly reduced the testicular relapse rate. In the L95-14 study, gender difference disappeared in EFS. Contrary to the results of larger-scale studies, the randomized control study in the L952-14 reconfirmed with updated data that dexamethasone 8 mg/m2 had no advantage over prednisolone 60 mg/m2 in the SR and intermediate-risk groups. Prophylactic cranial irradiation was assigned to 100, 80, 44, and 44% of the patients in the studies, respectively. Isolated central nervous system relapse rates decreased to <2% in the last two trials. Secondary brain tumors developed in 12 patients at 8-22 years after cranial irradiation. Improvement of the remission induction rates and the complete omission of irradiation are currently main objectives in our studies.

Original languageEnglish
Pages (from-to)383-396
Number of pages14
JournalLeukemia
Volume24
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Tokyo
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Cranial Irradiation
Neoplasms
Recurrence
Remission Induction
Prednisolone
Methotrexate
Brain Neoplasms
Dexamethasone
Central Nervous System
Survival
Therapeutics
Infection

Keywords

  • Acute lymphoblastic leukemia
  • Children
  • Cranial irradiation
  • Long-term results
  • Secondary malignancy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999. / Tsuchida, M.; Ohara, A.; Manabe, A.; Kumagai, M.; Shimada, Hiroyuki; Kikuchi, A.; Mori, T.; Saito, M.; Akiyama, M.; Fukushima, T.; Koike, K.; Shiobara, M.; Ogawa, C.; Kanazawa, T.; Noguchi, Y.; Oota, S.; Okimoto, Y.; Yabe, H.; Kajiwara, M.; Tomizawa, D.; Ko, K.; Sugita, K.; Kaneko, T.; Maeda, M.; Inukai, T.; Goto, H.; Takahashi, H.; Isoyama, K.; Hayashi, Y.; Hosoya, R.; Hanada, R.

In: Leukemia, Vol. 24, No. 2, 02.2010, p. 383-396.

Research output: Contribution to journalArticle

Tsuchida, M, Ohara, A, Manabe, A, Kumagai, M, Shimada, H, Kikuchi, A, Mori, T, Saito, M, Akiyama, M, Fukushima, T, Koike, K, Shiobara, M, Ogawa, C, Kanazawa, T, Noguchi, Y, Oota, S, Okimoto, Y, Yabe, H, Kajiwara, M, Tomizawa, D, Ko, K, Sugita, K, Kaneko, T, Maeda, M, Inukai, T, Goto, H, Takahashi, H, Isoyama, K, Hayashi, Y, Hosoya, R & Hanada, R 2010, 'Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999', Leukemia, vol. 24, no. 2, pp. 383-396. https://doi.org/10.1038/leu.2009.260
Tsuchida, M. ; Ohara, A. ; Manabe, A. ; Kumagai, M. ; Shimada, Hiroyuki ; Kikuchi, A. ; Mori, T. ; Saito, M. ; Akiyama, M. ; Fukushima, T. ; Koike, K. ; Shiobara, M. ; Ogawa, C. ; Kanazawa, T. ; Noguchi, Y. ; Oota, S. ; Okimoto, Y. ; Yabe, H. ; Kajiwara, M. ; Tomizawa, D. ; Ko, K. ; Sugita, K. ; Kaneko, T. ; Maeda, M. ; Inukai, T. ; Goto, H. ; Takahashi, H. ; Isoyama, K. ; Hayashi, Y. ; Hosoya, R. ; Hanada, R. / Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999. In: Leukemia. 2010 ; Vol. 24, No. 2. pp. 383-396.
@article{743e87eefe68429381bd51b9f69990e4,
title = "Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999",
abstract = "We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999. The value of event-free survival (EFS)s.±e. was 67.2±2.2{\%} at 10 years in L84-11, which was not improved in the following two studies, and eventually improved to 75.0±1.8{\%} at 10 years in L95-14 study. The lower EFS of the L89-12 reflected a high rate of induction failure because of infection and delayed remission in very high-risk patients. The L92-13 study was characterized by short maintenance therapy; it resulted in poor EFS, particularly in the standard-risk (SR) group and boys. Females did significantly better than males in EFS in the early three studies. The gender difference was not significant in overall survival, partly because >60{\%} of the males survived after the testicular relapse. Randomized studies in the former three protocols revealed that intermediate-or high-dose methotrexate therapy significantly reduced the testicular relapse rate. In the L95-14 study, gender difference disappeared in EFS. Contrary to the results of larger-scale studies, the randomized control study in the L952-14 reconfirmed with updated data that dexamethasone 8 mg/m2 had no advantage over prednisolone 60 mg/m2 in the SR and intermediate-risk groups. Prophylactic cranial irradiation was assigned to 100, 80, 44, and 44{\%} of the patients in the studies, respectively. Isolated central nervous system relapse rates decreased to <2{\%} in the last two trials. Secondary brain tumors developed in 12 patients at 8-22 years after cranial irradiation. Improvement of the remission induction rates and the complete omission of irradiation are currently main objectives in our studies.",
keywords = "Acute lymphoblastic leukemia, Children, Cranial irradiation, Long-term results, Secondary malignancy",
author = "M. Tsuchida and A. Ohara and A. Manabe and M. Kumagai and Hiroyuki Shimada and A. Kikuchi and T. Mori and M. Saito and M. Akiyama and T. Fukushima and K. Koike and M. Shiobara and C. Ogawa and T. Kanazawa and Y. Noguchi and S. Oota and Y. Okimoto and H. Yabe and M. Kajiwara and D. Tomizawa and K. Ko and K. Sugita and T. Kaneko and M. Maeda and T. Inukai and H. Goto and H. Takahashi and K. Isoyama and Y. Hayashi and R. Hosoya and R. Hanada",
year = "2010",
month = "2",
doi = "10.1038/leu.2009.260",
language = "English",
volume = "24",
pages = "383--396",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999

AU - Tsuchida, M.

AU - Ohara, A.

AU - Manabe, A.

AU - Kumagai, M.

AU - Shimada, Hiroyuki

AU - Kikuchi, A.

AU - Mori, T.

AU - Saito, M.

AU - Akiyama, M.

AU - Fukushima, T.

AU - Koike, K.

AU - Shiobara, M.

AU - Ogawa, C.

AU - Kanazawa, T.

AU - Noguchi, Y.

AU - Oota, S.

AU - Okimoto, Y.

AU - Yabe, H.

AU - Kajiwara, M.

AU - Tomizawa, D.

AU - Ko, K.

AU - Sugita, K.

AU - Kaneko, T.

AU - Maeda, M.

AU - Inukai, T.

AU - Goto, H.

AU - Takahashi, H.

AU - Isoyama, K.

AU - Hayashi, Y.

AU - Hosoya, R.

AU - Hanada, R.

PY - 2010/2

Y1 - 2010/2

N2 - We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999. The value of event-free survival (EFS)s.±e. was 67.2±2.2% at 10 years in L84-11, which was not improved in the following two studies, and eventually improved to 75.0±1.8% at 10 years in L95-14 study. The lower EFS of the L89-12 reflected a high rate of induction failure because of infection and delayed remission in very high-risk patients. The L92-13 study was characterized by short maintenance therapy; it resulted in poor EFS, particularly in the standard-risk (SR) group and boys. Females did significantly better than males in EFS in the early three studies. The gender difference was not significant in overall survival, partly because >60% of the males survived after the testicular relapse. Randomized studies in the former three protocols revealed that intermediate-or high-dose methotrexate therapy significantly reduced the testicular relapse rate. In the L95-14 study, gender difference disappeared in EFS. Contrary to the results of larger-scale studies, the randomized control study in the L952-14 reconfirmed with updated data that dexamethasone 8 mg/m2 had no advantage over prednisolone 60 mg/m2 in the SR and intermediate-risk groups. Prophylactic cranial irradiation was assigned to 100, 80, 44, and 44% of the patients in the studies, respectively. Isolated central nervous system relapse rates decreased to <2% in the last two trials. Secondary brain tumors developed in 12 patients at 8-22 years after cranial irradiation. Improvement of the remission induction rates and the complete omission of irradiation are currently main objectives in our studies.

AB - We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999. The value of event-free survival (EFS)s.±e. was 67.2±2.2% at 10 years in L84-11, which was not improved in the following two studies, and eventually improved to 75.0±1.8% at 10 years in L95-14 study. The lower EFS of the L89-12 reflected a high rate of induction failure because of infection and delayed remission in very high-risk patients. The L92-13 study was characterized by short maintenance therapy; it resulted in poor EFS, particularly in the standard-risk (SR) group and boys. Females did significantly better than males in EFS in the early three studies. The gender difference was not significant in overall survival, partly because >60% of the males survived after the testicular relapse. Randomized studies in the former three protocols revealed that intermediate-or high-dose methotrexate therapy significantly reduced the testicular relapse rate. In the L95-14 study, gender difference disappeared in EFS. Contrary to the results of larger-scale studies, the randomized control study in the L952-14 reconfirmed with updated data that dexamethasone 8 mg/m2 had no advantage over prednisolone 60 mg/m2 in the SR and intermediate-risk groups. Prophylactic cranial irradiation was assigned to 100, 80, 44, and 44% of the patients in the studies, respectively. Isolated central nervous system relapse rates decreased to <2% in the last two trials. Secondary brain tumors developed in 12 patients at 8-22 years after cranial irradiation. Improvement of the remission induction rates and the complete omission of irradiation are currently main objectives in our studies.

KW - Acute lymphoblastic leukemia

KW - Children

KW - Cranial irradiation

KW - Long-term results

KW - Secondary malignancy

UR - http://www.scopus.com/inward/record.url?scp=76749093120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749093120&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.260

DO - 10.1038/leu.2009.260

M3 - Article

C2 - 20033052

AN - SCOPUS:76749093120

VL - 24

SP - 383

EP - 396

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -